ECSP045407A - Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf - Google Patents

Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf

Info

Publication number
ECSP045407A
ECSP045407A EC2004005407A ECSP045407A ECSP045407A EC SP045407 A ECSP045407 A EC SP045407A EC 2004005407 A EC2004005407 A EC 2004005407A EC SP045407 A ECSP045407 A EC SP045407A EC SP045407 A ECSP045407 A EC SP045407A
Authority
EC
Ecuador
Prior art keywords
quinasa
benzazoles
raf
inhibitors
substituted
Prior art date
Application number
EC2004005407A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045407A publication Critical patent/ECSP045407A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los nuevos compuestos benz-azole sustituidos de la fórmula (I), las composiciones y métodos de inhibición de la actividad quinasa Raf en un sujeto humano o animal son provistos. Las nuevas composiciones de los compuestos pueden ser usadas solos o en combinación con por lo menos un agente adicional para el tratamiento de una enfermedad mediada por quinasa Raf, como es el cáncer.
EC2004005407A 2002-03-29 2004-10-29 Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf ECSP045407A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36906602P 2002-03-29 2002-03-29

Publications (1)

Publication Number Publication Date
ECSP045407A true ECSP045407A (es) 2005-01-03

Family

ID=28675563

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005407A ECSP045407A (es) 2002-03-29 2004-10-29 Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf

Country Status (26)

Country Link
US (3) US7071216B2 (es)
EP (1) EP1499311B1 (es)
JP (3) JP4628678B2 (es)
KR (2) KR20110015702A (es)
CN (1) CN100515419C (es)
AP (1) AP1913A (es)
AT (1) ATE447404T1 (es)
AU (1) AU2003226211B2 (es)
BR (1) BR0308854A (es)
CA (1) CA2480638C (es)
CO (1) CO5611108A2 (es)
CY (1) CY1109764T1 (es)
DE (1) DE60329910D1 (es)
DK (1) DK1499311T3 (es)
EA (1) EA007987B1 (es)
EC (1) ECSP045407A (es)
ES (1) ES2336094T3 (es)
IL (2) IL164302A0 (es)
MX (1) MXPA04009541A (es)
NO (1) NO330563B1 (es)
NZ (1) NZ535985A (es)
PL (2) PL214800B1 (es)
PT (1) PT1499311E (es)
SI (1) SI1499311T1 (es)
WO (1) WO2003082272A1 (es)
ZA (1) ZA200408386B (es)

Families Citing this family (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
ES2336094T3 (es) 2002-03-29 2010-04-08 Novartis Vaccines And Diagnostics, Inc. Benzazoles sustituidos y uso de los mismos como inhibidores de quinasa raf.
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
DE10224892A1 (de) * 2002-06-04 2003-12-18 Aventis Pharma Gmbh Substituierte Thiophene, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
EP2258365B1 (en) * 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
KR20060025141A (ko) 2003-05-15 2006-03-20 아르퀼 인코포레이티드 Ｐ38의 억제제 및 이를 사용하는 방법
US20070020704A1 (en) 2003-05-20 2007-01-25 Scott Wilhelm Diaryl ureas with kinase inhibiting activity
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
ES2327418T3 (es) 2003-10-16 2009-10-29 Novartis Vaccines And Diagnostics, Inc. Benzazoles sustituidos y uso de los mismos como inhibidores de la quinasa raf.
DE10349587A1 (de) 2003-10-24 2005-05-25 Merck Patent Gmbh Benzimidazolylderivate
CN1905873A (zh) * 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
WO2005070891A2 (en) 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
MXPA06014696A (es) * 2004-06-15 2007-02-12 Astrazeneca Ab Quinazolonas sustituidas como agentes anticancerosos.
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
US7829560B2 (en) * 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
EP2532653A1 (en) * 2004-08-25 2012-12-12 Targegen, Inc. Benzo[1,2,4]triazines as protein kinase modulators
AU2005278959A1 (en) * 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as B-Raf inhibitors
KR20070055575A (ko) * 2004-09-01 2007-05-30 아스트라제네카 아베 퀴나졸리논 유도체 및 이의 ｂ―ｒａｆ 억제제로서의 용도
CA2583096A1 (en) * 2004-10-15 2006-04-20 Astrazeneca Ab Quinoxalines as b raf inhibitors
EP2258704A1 (en) * 2004-10-19 2010-12-08 ArQule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
ATE542564T1 (de) * 2004-11-05 2012-02-15 Icu Medical Inc Medizinischer konnektor mit hohen durchflusseigenschaften
JP2008521900A (ja) 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
MX2007007574A (es) * 2004-12-22 2007-07-24 Astrazeneca Ab Derivados de piridina-carboxamida para uso como agentes anticancerosos.
US7576090B2 (en) * 2004-12-27 2009-08-18 4Sc Ag Benzazole analogues and uses thereof
EP1674466A1 (en) * 2004-12-27 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors
US7429608B2 (en) * 2005-01-20 2008-09-30 Amgen Inc. Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments
AU2006208834A1 (en) * 2005-01-25 2006-08-03 Astrazeneca Ab Chemical compounds
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
PT2351772T (pt) 2005-02-18 2016-09-22 Glaxosmithkline Biologicals Sa Proteínas e ácidos nucleicos de escherichia coli associada a meningite/septicemia
NZ560929A (en) 2005-02-18 2009-12-24 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2006124780A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
US20100017895A1 (en) 2005-07-18 2010-01-21 Amy Weiner Small animal model for hcv replication
CN101253169B (zh) * 2005-08-30 2011-11-23 诺瓦提斯公司 取代的苯并咪唑及其制备方法
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
JP4887368B2 (ja) 2005-10-13 2012-02-29 スミスクライン ビーチャム コーポレーション 新規ヘテロ環化合物
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
PL1951299T3 (pl) 2005-11-04 2012-07-31 Novartis Ag Szczepionki przeciw grypie zawierające kombinacje adiuwantów cząsteczkowych i czynników wzmacniających immunogenność
NZ567979A (en) 2005-11-04 2012-02-24 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7
JP2009514850A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
US20080306096A1 (en) * 2005-12-22 2008-12-11 Astrazeneca Ab Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents
WO2007076474A1 (en) * 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
EP1982718A4 (en) 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF CANCER
WO2007095124A2 (en) * 2006-02-10 2007-08-23 Transtech Pharma, Inc. Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
AU2007227681A1 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
EP2019686B1 (en) 2006-03-31 2012-07-11 Novartis AG Combined mucosal and parenteral immunization against hiv
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
AU2007237904B2 (en) 2006-04-19 2011-03-03 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
JP2009537542A (ja) 2006-05-19 2009-10-29 ワイス ヒスタミン−３アンタゴニストとしてのｎ−ベンゾイルピロリジン−３−イルアミンおよびｎ−ベンジルピロリジン−３−イルアミン
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
US7932390B2 (en) * 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
MX2009000770A (es) * 2006-07-21 2009-01-28 Novartis Ag Formulaciones para eteres de piridilo de bencimidazolilo.
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
PE20130814A1 (es) * 2006-08-30 2013-08-08 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen
BRPI0716549A2 (pt) * 2006-09-07 2013-09-24 Biogen Idec Inc moduladores de quinase associada de interleucina-1
BRPI0716536A2 (pt) 2006-09-11 2013-09-24 Novartis Ag produÇço de vacinas de vÍrus influenza, sem a utilizaÇço de ovos
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
US20110045022A1 (en) 2006-12-06 2011-02-24 Theodore Tsai Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
WO2008140850A1 (en) * 2007-03-02 2008-11-20 Novartis Ag Solid forms of a raf kinase inhibitor
ES2452349T3 (es) * 2007-05-21 2014-04-01 Novartis Ag Inhibidores de CSF-1R, composiciones, y métodos de uso
CL2008001626A1 (es) * 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
CA2693138A1 (en) 2007-07-16 2009-01-22 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
EP2181987B9 (en) * 2007-08-23 2014-09-03 Takeda Pharmaceutical Company Limited 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer
WO2009028629A1 (ja) * 2007-08-29 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
WO2009028655A1 (ja) * 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
PT2209778E (pt) 2007-09-21 2012-12-06 Array Biopharma Inc Derivados de piridin-2-il-amino-1,2,4-tiadiazole como activadores de glucoquinase para o tratamento de diabetes mellitus
EP2211862A2 (en) * 2007-10-18 2010-08-04 Novartis AG Csf-1r inhibitors for treatment of cancer and bone diseases
AU2008319366B2 (en) * 2007-10-29 2012-03-01 Amgen Inc. Benzomorpholine derivatives and methods of use
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
JP2011506560A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2009222144A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Pyrazole [3, 4-b] pyridine Raf inhibitors
EP2265574A1 (en) * 2008-02-29 2010-12-29 Array Biopharma, Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
AR070535A1 (es) * 2008-02-29 2010-04-14 Array Biopharma Inc Compuestos inhibidores de raf y metodos para usarlos
WO2009111277A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
EP2288354A1 (en) * 2008-06-13 2011-03-02 Novartis AG Substituted benzimidazoles for neurofibromatosis
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
AU2009322158A1 (en) * 2008-12-05 2010-06-10 Arqule, Inc. RAF inhibitors and their uses
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2010100632A2 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
NZ595689A (en) 2009-04-14 2014-03-28 Novartis Ag Compositions for immunising against staphylococcus aureus
KR20120027276A (ko) 2009-04-27 2012-03-21 노파르티스 아게 인플루엔자를 예방하기 위한 면역증강된 백신
US9125901B2 (en) 2009-06-23 2015-09-08 The Translational Genomics Research Institute 4-(benzimidazol-2-ylamino)benzamide derivatives and salts or solvates thereof
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
WO2011004263A2 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
CN102639147B (zh) 2009-07-15 2015-11-25 诺华股份有限公司 Rsv f 蛋白组合物和其制作方法
DK2464658T3 (en) 2009-07-16 2014-12-15 Novartis Ag Detoxified escherichia coli immunogens
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
ES2707778T3 (es) 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US9120752B2 (en) 2010-07-16 2015-09-01 Purdue Pharma, L.P. Pyridine compounds as sodium channel blockers
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
AU2011303597A1 (en) 2010-09-17 2013-04-11 Purdue Pharma L.P. Pyridine compounds and the uses thereof
PL2730564T3 (pl) * 2010-11-19 2018-09-28 Ligand Pharmaceuticals Inc. Heterocykliczne aminy i ich zastosowania
US8674113B2 (en) 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
AU2012211278B2 (en) 2011-01-26 2016-11-10 Glaxosmithkline Biologicals Sa RSV immunization regimen
EA025011B1 (ru) 2011-01-31 2016-11-30 Новартис Аг ПУРИНЫ, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR КИНАЗЫ, ИХ ИСПОЛЬЗОВАНИЕ И ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
NO2707385T3 (es) 2011-05-13 2018-02-17
CN103764171B (zh) 2011-07-08 2016-08-17 诺华股份有限公司 酪氨酸连接方法
CN102432595B (zh) * 2011-09-14 2013-09-25 湖南有色凯铂生物药业有限公司 N-吲哚-1-酰胺类化合物及作为抗癌药物的应用
US9334271B2 (en) 2011-10-28 2016-05-10 Novarits Ag Purine derivatives and their use in the treatment of disease
CA2854934A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
WO2013136170A1 (en) 2012-03-16 2013-09-19 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
JP6381523B2 (ja) 2012-05-16 2018-08-29 ノバルティス アーゲー Ｐｉ−３キナーゼ阻害剤の投与レジメン
JP2015532276A (ja) 2012-10-02 2015-11-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 非直鎖状糖コンジュゲート
HUE036158T2 (hu) 2012-11-30 2018-06-28 Glaxosmithkline Biologicals Sa Pseudomonas antigének és antigén kombinációk
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9556170B2 (en) 2013-08-30 2017-01-31 University Of Utah Research Foundation Substituted-1H-benzo[d]imidazole series compounds as lysine-specific demethylase 1 (LSD1) inhibitors
CN103450093A (zh) * 2013-09-06 2013-12-18 中国药科大学 2-苄氨基苯并咪唑类化合物及其用途
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
WO2015083101A1 (en) 2013-12-06 2015-06-11 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
KR20160106627A (ko) * 2013-12-30 2016-09-12 라이프에스씨아이 파마슈티컬스, 인크. 치료적 억제 화합물
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
EP3233087B1 (en) 2014-12-16 2019-10-02 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
CN105949178B (zh) * 2015-03-09 2020-05-26 西格莱(苏州)生物医药有限公司 一种苯并咪唑类化合物、其制备方法、中间体及应用
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
KR20180044256A (ko) 2015-06-10 2018-05-02 엑소반트 사이언시즈 게엠베하 A7-니코틴성 아세틸콜린 수용체의 작용제로서의 아미노벤즈이소옥사졸 화합물
HK1253295A1 (zh) 2015-08-12 2019-06-14 Axovant Sciences Gmbh 作为7-烟碱乙酰胆碱受体的激动剂的偕取代的氨基苯并异恶唑化合物
KR101770310B1 (ko) 2015-08-24 2017-08-24 이화여자대학교 산학협력단 2-(페닐아미노)벤조[d]옥사졸-5-올 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
MX2018005298A (es) 2015-11-02 2018-06-22 Novartis Ag Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
JP7094942B2 (ja) * 2017-03-15 2022-07-04 住友ファーマ株式会社 ベンズイミダゾール誘導体の製造方法
MX393855B (es) 2017-05-02 2025-03-21 Novartis Ag Terapia de combinación que comprende un inhibidor de raf y trametinib
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
US12522583B2 (en) * 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097398A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
CN111848505B (zh) * 2019-04-26 2024-08-20 广东东阳光药业股份有限公司 一种伐度司他中间体的制备方法
AU2020276695B2 (en) 2019-05-13 2025-12-18 Novartis Ag New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as RAF inhibitors for the treatment of cancer
WO2021066608A1 (ko) * 2019-10-02 2021-04-08 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물 및 이의 용도
CN111138428B (zh) * 2019-12-26 2021-02-19 深圳市老年医学研究所 一种非洲防己碱制备方法以及非洲防己碱
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2022133098A2 (en) * 2020-12-16 2022-06-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
GB2618017B (en) * 2021-01-29 2025-04-30 Korea Res Inst Chemical Tech Benzothiazole and benzimidazole derivatives, pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition comprising
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN114276266B (zh) * 2021-12-30 2024-10-11 兰州康鹏威耳化工有限公司 一种4-氨基-2-氟苯甲酰胺的制备方法
EP4673137A1 (en) * 2023-03-02 2026-01-07 Sionna Therapeutics Inc. Nbd1 modulators and methods of using the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63190880A (ja) * 1986-09-09 1988-08-08 Nippon Tokushu Noyaku Seizo Kk 新規ｎ−ベンゾチアゾリル−アミド類及び殺虫剤
US6248771B1 (en) 1997-03-05 2001-06-19 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
JP2002502844A (ja) * 1998-02-03 2002-01-29 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト ５員複素環縮合ベンゾ誘導体、その調製及び医薬品としてのそれらの使用
HK1038564A1 (zh) * 1998-10-08 2002-03-22 Smithkline Beecham Plc 用作糖原合酶激酶-3抑制劑的吡咯-2，5-二酮
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CN1350534A (zh) * 1999-04-12 2002-05-22 阿文蒂斯药物有限公司 作为整联蛋白拮抗剂的取代双环杂芳基化合物
KR100722344B1 (ko) * 1999-04-15 2007-05-29 브리스톨-마이어스스퀴브컴파니 환형 단백질 티로신 키나제 억제제
WO2001021598A1 (en) 1999-09-23 2001-03-29 Astrazeneca Ab Therapeutic quinazoline compounds
ES2218391T3 (es) * 2000-03-06 2004-11-16 Smithkline Beecham Plc Derivados de imidazol como inhibidores de raf-cinasa.
DE60120881T2 (de) * 2000-04-07 2007-01-18 Samsung Electronics Co., Ltd., Suwon Sulfonamide als matrix-metalloproteinase inhibitoren
WO2002042273A2 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
JP2004517080A (ja) 2000-11-29 2004-06-10 グラクソ グループ リミテッド Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
RU2290403C2 (ru) * 2000-12-28 2006-12-27 Дайити Фармасьютикал Ко., Лтд. Ингибиторы vla-4
WO2002076960A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transition metal mediated process
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
FR2833948B1 (fr) * 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
WO2003074515A1 (en) * 2002-03-01 2003-09-12 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
ES2336094T3 (es) * 2002-03-29 2010-04-08 Novartis Vaccines And Diagnostics, Inc. Benzazoles sustituidos y uso de los mismos como inhibidores de quinasa raf.
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
EP2258365B1 (en) * 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
AU2007237904B2 (en) * 2006-04-19 2011-03-03 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling

Also Published As

Publication number Publication date
US8614330B2 (en) 2013-12-24
EP1499311A1 (en) 2005-01-26
CN100515419C (zh) 2009-07-22
DE60329910D1 (de) 2009-12-17
JP2006193533A (ja) 2006-07-27
US20040087626A1 (en) 2004-05-06
BR0308854A (pt) 2005-02-22
DK1499311T3 (da) 2010-03-08
PT1499311E (pt) 2010-03-10
HK1078779A1 (zh) 2006-03-24
IL164302A0 (en) 2005-12-18
EP1499311B1 (en) 2009-11-04
JP2005529089A (ja) 2005-09-29
KR20110015702A (ko) 2011-02-16
AP1913A (en) 2008-10-31
EA007987B1 (ru) 2007-02-27
CY1109764T1 (el) 2014-09-10
EA200401284A1 (ru) 2005-04-28
PL372852A1 (en) 2005-08-08
MXPA04009541A (es) 2005-01-25
ES2336094T3 (es) 2010-04-08
ZA200408386B (en) 2006-05-31
WO2003082272A1 (en) 2003-10-09
CA2480638C (en) 2013-02-12
NZ535985A (en) 2007-04-27
PL214800B1 (pl) 2013-09-30
NO330563B1 (no) 2011-05-16
CA2480638A1 (en) 2003-10-09
KR101071123B1 (ko) 2011-10-07
US7728010B2 (en) 2010-06-01
CO5611108A2 (es) 2006-02-28
CN1655779A (zh) 2005-08-17
JP2010275317A (ja) 2010-12-09
AP2004003161A0 (en) 2004-12-31
US20100196368A1 (en) 2010-08-05
AU2003226211A1 (en) 2003-10-13
HK1067945A1 (en) 2005-04-22
ATE447404T1 (de) 2009-11-15
PL402389A1 (pl) 2013-04-02
SI1499311T1 (sl) 2010-03-31
JP5265629B2 (ja) 2013-08-14
US7071216B2 (en) 2006-07-04
NO20044617L (no) 2004-12-28
JP4628678B2 (ja) 2011-02-09
AU2003226211B2 (en) 2008-05-29
KR20040095355A (ko) 2004-11-12
IL164302A (en) 2010-12-30
US20070299039A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
CU20080027A7 (es) Bencimidazoles sustituidos como inhibidores de cinasa
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
ECSP056131A (es) Compuestos de carbonilo
UY32085A (es) Inhibidores de cinasa y métodos para su uso
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
UY29633A1 (es) Derivados de oxindol
ECSP055840A (es) Derivados de 4 -tetrazolil-4fenilpiperidina para el tratamiento del dolor
AR023400A1 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
AR051446A1 (es) Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
AR054094A1 (es) Tratamientos de cancer
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
UY28271A1 (es) Compuestos químicos
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
CO2022016153A2 (es) Inhibidores de il4i1 y métodos de uso
ECSP066805A (es) Compuestos silinano como inhibidores de cisteína proteasa
BRPI0414114A (pt) uso de defibrotide, formulação, e, método para tratar um mamìfero afetado por um tumor
AR057648A1 (es) Composicion de metaflumizona para la administracion topica
ES2421520T3 (es) Potenciador de la producción de adiponectina
SV2008002831A (es) Bencimidazoles sustituidos como inhibidores de cinasa